ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Mar 14, 2022 20:58 JST
Source:
Jacobson Pharma Corporation Limited
Jacobson Pharma's Chairman Uplifts Shareholding to Above 60%
Demonstrates Confidence in Group's Long-term Prospects
HONG KONG, Mar 14, 2022 - (ACN Newswire) - Mr. Derek Sum, Chairman and Chief Executive Officer of Jacobson Pharma Corporation Limited (the "Company"; together with its subsidiaries, the "Group"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of essential medicines, specialty drugs and branded healthcare products, acquired through his controlled entity a total of 20,532,000 shares of the Company (the "Shares") between 15 December 2021 and 14 March 2022 on the market at a total consideration of approximately HK$13,460,000, representing an average price of approximately HK$0.6555 per Share (the "Acquisitions").
The above share purchase represents approximately 1.06% of the total issued share capital of the Company as at 14 March 2022. Following the Acquisitions, Mr. Sum is interested in an aggregate of 1,160,808,000 Shares, representing approximately 60.01% of the total issued share capital of the Company as at the date of the related announcement.
Speaking with sound optimism about the future prospects of the Group, Mr. Sum went on to say, "Albeit the challenging market environment, the overall business, in particular the generic drugs, has shown great strength and resilience in the face of the ongoing pandemic. We remain steadfast to realize the growth potential of our robust product portfolios alongside a strong commercial and operational set-up. I have strong confidence in the long-term development of the Group."
Mr Sum said he might consider further increasing his shareholding in the Company subject to the applicable laws and regulations.
About Jacobson Pharma Corporation Limited (Stock Code: 2633)
Jacobson Pharma is a leading pharmaceutical company in Hong Kong vertically integrated engaged in the research, development, production, sale and distribution of essential medicines and specialty drugs. As a major provider of generic drugs in Hong Kong, the Group has one of the most extensive sales and distribution coverage for both the private and public market sectors in Hong Kong, with an expanding reach into strategically selected Asian markets. Carrying a broad product portfolio and taking a pre-eminent market position in a number of therapeutic categories, the Group operates a host of 10 PIC/S GMP licensed production facilities for generic drugs in Hong Kong.
The Group aims at the continued strategic enrichment of its generic drug portfolios through the addition of high value-added products. With its corporate headquarters based in Hong Kong, the Group has also established its operating subsidiaries in China, Macau, Taiwan, Singapore and Cambodia forming a regional commercial platform to tap the market potential in the Asia Pacific and Greater China region. Jacobson Pharma has been a constituent stock of MSCI Hong Kong Micro Cap Index since 1 June 2017. For more details about Jacobson Pharma, please visit the Group's website:
http://www.jacobsonpharma.com
For media enquiries, please contact:
Strategic Financial Relations Limited
Vicky Lee Tel: (852) 2864 4834 Email:
vicky.lee@sprg.com.hk
Rachel Ko Tel: (852) 2114 2370 Email:
rachel.ko@sprg.com.hk
Mandy Wong Tel: (852) 2114 4900 Email:
mandy.wong@sprg.com.hk
Fax: (852) 2527 1196
Source: Jacobson Pharma Corporation Limited
Sectors: Daily Finance, BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
JCB enables JCB Contactless acceptance at Taichung MRT in Taiwan
Apr 26, 2024 10:00 JST
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
More Latest Release >>
Related Release
Jacobson Pharma Announces FY2023 Interim Results
November 25 2022 21:21 JST
Jacobson Pharma Announces FY2022 Annual Results
June 29 2022 23:20 JST
Ban Loong, Jacobson & JBM Form Joint Venture to Tap Specialty Drugs and Branded Healthcare Markets in Greater China and Asia
June 15 2022 19:56 JST
Jacobson Pharma Announces FY2022 Interim Results
November 26 2021 19:39 JST
Jacobson Pharma Announces FY2021 Annual Results
June 29 2021 23:19 JST
JBM (Healthcare) Limited Debuts on The Main Board of SEHK
February 05 2021 16:28 JST
JBM (Healthcare) Limited to Be Spun Off from Jacobson Pharma Corporation Limited
January 25 2021 17:20 JST
Jacobson Pharma's Proposed Spin-off and Separate Listing of JBM (Healthcare) Limited on The Main Board of The Stock Exchange of Hong Kong Limited
January 15 2021 23:25 JST
Jacobson Pharma Announces FY2021 Interim Results
November 27 2020 20:10 JST
Jacobson Pharma Submits Form A1 to Spin-off Its Branded Healthcare Business
September 23 2020 20:30 JST
More Press release >>